We are a strong team of creative individuals dedicated to improving the treatment of acute decompensated heart failure (ADHF). Our first principles approach led us to realize the potential for harnessing the body’s own lymphatic system to deliver a different approach to restoring fluid balance in ADHF patients.
We are a science-driven team of curious, creative, committed individuals dedicated to improving the treatment of acute decompensated heart failure.
Eamon Brady Chief Executive Officer
Chief Executive Officer
Eamon Brady is the CEO of WhiteSwell, leading the charge to develop an innovative new therapy for Acute Decompensated Heart Failure by drawing upon the tissue drainage power of the body’s own lymphatic system. He honed his experience in science-driven device development as founder and CEO of Neuravi, where he built a company which treated over 5,000 acute ischemic stroke patients before it was acquired by Johnson and Johnson. He was also a founding member and head of R&D at MedNova Ltd, a company that pioneered carotid stenting and was acquired by Abbott Vascular. Eamon is passionate about bringing medical therapies to market that impact patients with poor prognostic outlook and he sees team building and technological innovation as critical to better patient outcomes. When he isn’t encouraging his team to challenge themselves to continuously improve, Eamon relaxes by working the land in his home near Galway.
Ann Marie Cannon VP Quality & Regulatory Affairs
VP Quality & Regulatory Affairs
Ann Marie Cannon is the VP of Quality and Regulatory Affairs, dedicated to delivering a high quality WhiteSwell system for treating ADHF patients. With extensive experience in developing medical device quality systems and regulatory strategies, she most recently was Director of Quality and Regulatory Affairs at Marvao Medical where she built an ISO 13485 and QSR compliant quality system, created a regulatory strategy, and led clinical trials, culminating with both CE Mark and FDA clearance. Ann Marie believes that doing things the right way with a commitment to the highest standard is vital when bringing new therapies to market. She holds a Bachelors degree in Biochemistry and a Masters degree in Biotechnology from the University of Galway. To facilitate clarity of thought, Ann Marie enjoys walking in the bracing air of the rugged coastline of the west of Ireland.
Ronan Keating VP Research & Development
VP Research & Development
Ronan Keating is the VP of R&D at WhiteSwell, guiding development of an innovative treatment to target interstitial decongestion in Acute Decompensated Heart Failure patients. Ronan is an experienced R&D leader, having most recently served as CTO and founder at neoSurgical where his team developed a first of its kind absorbable tissue approximation implant, taking it from concept to regulatory approval to commercialization. Prior to this Ronan led EmboShield Embolic Protection R&D programs at Abbott Vascular and Mednova. He strongly advocates Design from First Principles and Design for Manufacture as essential for groundbreaking innovation and he strives to create products that address complex performance requirements with robust engineering and streamlined design. A Biomedical Engineer with a portfolio of circa 30 patents, he also holds a Masters Degree in Computational Fluid Dynamics. Ronan is an avid off-road cyclist who enjoys spending his free time crisscrossing the rocky landscapes of the west of Ireland and further afield whenever possible.
Sergio Shkurovich VP Clinical Affairs
VP Clinical Affairs
Sergio Shkurovich is the VP of Clinical Affairs at WhiteSwell, where he is enthusiastic about leading the clinical program to build the evidence supporting the safety and efficacy of interstitial decongestion in acute heart failure patients. Over the last 20 years, he has honed his skills in clinical strategy and execution leading clinical research programs at V-Wave, Medtronic and St. Jude Medical (Abbott). He has a BSE in Electrical Engineering from the National University of Mexico, and a PhD in Biomedical Engineering and an MBA from Northwestern University. Energetically pursuing excellence at work, Sergio carries that competitive spirit to the tennis court as a player and fan and is most proud of his family.
Jill Amstutz VP Strategic Marketing
VP Strategic Marketing
Jill Amstutz is the VP of Strategic Marketing for WhiteSwell, where she is inspired by the opportunity to provide a valuable new approach to heart failure therapy that will help patients and clinicians. She strongly believes in the importance of developing the scientific support for new innovation. Most recently, as VP of Global Marketing at Neuravi, she launched programs including the Clot Summit which sought to advance the treatment of acute ischemic stroke through scientific research on stroke-causing thrombi. She has worked on a number of cardiovascular products at start-ups like Sadra Medical and larger corporations such as Guidant and Abbott Vascular. She has an MBA from the Stanford Graduate School of Business and a Bachelor’s degree from Princeton University. When she is not asking why, Jill enjoys hiking and being immersed in the sights, sounds and scents of nature.
Martin Keegan VP Technical Operations
VP Technical Operations
As the VP of Technical Operations, Martin Keegan oversees a world-wide network of suppliers to deliver high quality precision-engineered products. Most recently as Technical Operations Director at Boston Scientific, he was responsible for manufacturing, process optimization and validation, and led a successful technology transfer program. He brings to WhiteSwell a breadth of experience spanning endovascular medical devices to electronics, including hardware and software development. Martin delights in building cross-functional trans-national teams with an eye to excellence. He holds both a Bachelor’s and Master’s in Mechanical Engineering from University of Galway and is a Chartered Engineer. Fueled by fast-paced coordinated action and healthy competition, Martin dedicates time to two local water polo clubs as Team Manager.
Barry Kelly Head of Finance
Head of Finance
Barry Kelly is the Head of Finance at WhiteSwell, guiding the investment in the company to create value and drive growth. Prior to joining WhiteSwell, he led Business Operations, HR, and Finance at Link Financial, a Central Bank of Ireland regulated financial services provider. Barry has a passion for using data to inform strategic decision-making. He holds an HDip in Data Analytics from the Technological University of the Shannon and a Master of Accounting (MAcc) from University of Galway. He is also a Fellow of Chartered Accountants Ireland. When not focused on supporting team success at WhiteSwell, Barry is a sports enthusiast who avidly supports his hometown football team.
Andrew Levin Managing Director, RA Capital
Managing Director, RA Capital
Andrew Levin is Chairman of the Board of Directors at WhiteSwell, providing guidance to help the company develop what he believes will be a potentially game-changing therapy. He is passionate about developing new therapies as a Managing Director at RA Capital Management where he spearheads a drug discovery effort that has led to the formation of several new companies. Previously he served as Vice President at H.I.G. Bioventures and as Director of Pharmaceutical Sciences at the Clinton Health Access Initiative. He holds a BSE in Mechanical Engineering from Princeton University, a PhD in Biomedical Engineering from the Massachusetts Institute of Technology, and an MD from Harvard Medical School. When he isn’t growing companies, he spends time with his growing family.
Andrew Farquharson Managing Director & Co-Founder, InCube Ventures
Managing Director & Co-Founder, InCube Ventures
Andrew Farquharson is a Board member at WhiteSwell, facilitating connections, providing strategic perspective and supporting innovation. His strategic insights come from two decades of experience building, restructuring and acquiring life science companies as a founding member of InCube’s venture fund and as an advisor to InCube Labs, LLC. Andrew built a global sales force from scratch, grew revenues of synthetic DNA products to $40M in two years, and helped to negotiate a sale of Operon Technologies to QIAGEN for $150M. He holds a Masters of Business Administration from Harvard University and a Bachelor’s degree from the University of California at Berkeley. A connoisseur of craft beers, Andrew’s passion for innovation and appreciation of complexity imbue both his ventures and his leisure pursuits.
Doug Evans Chief Executive Officer, Lungpacer Medical Inc.
Chief Executive Officer, Lungpacer Medical Inc.
Doug Evans is on the Board of Directors at WhiteSwell, providing counsel, deep R&D experience and support to the leadership team. As CEO of Lungpacer, a company that helps protect the lungs and respiratory muscles of critically ill patients, he is devoted to addressing underserved clinical needs. His 30 years of experience includes serving as COO for Kensey Nash Corporation which was acquired for $360M by Royal DSM in 2012. He has authored over 175 patents and commercialized multiple leading-edge products in cardiology, orthopedics and general surgery. Doug holds a Bioengineering degree and MBA from Penn State, and a Master’s in Electrical Engineering and Photonics from the University of Pennsylvania. His commitment to addressing clinical challenges with improved therapy extends to his personal life, with his work as co-founder of the Cure4Cam Childhood Cancer Foundation.
Ric Cote CEO & President, Channel Medsystems
CEO & President, Channel Medsystems
Ric Cote is a Board member at WhiteSwell, lending his expertise in marketing, sales and reimbursement gained through commercializing multiple innovative medical devices. As CEO at Channel Medsystems, Ric leads a team committed to the empowerment of women to take control of their health. Previously, Ric served as EVP, Global Sales and Business Development at Conceptus, where he led the commercial team and built revenues from just over $4M to over $140M. Conceptus was acquired by Bayer in 2013. Prior to that, he successfully led the sales and marketing efforts at Influence Medical, which was acquired by AMS in 2000. Ric enjoys traveling with his family, playing golf and a good bottle of wine with friends.
Eamon Brady Chief Executive Officer
Chief Executive Officer
Eamon Brady is the CEO of WhiteSwell, leading the charge to develop an innovative new therapy for Acute Decompensated Heart Failure by drawing upon the tissue drainage power of the body’s own lymphatic system. He honed his experience in science-driven device development as founder and CEO of Neuravi, where he built a company which treated over 5,000 acute ischemic stroke patients before it was acquired by Johnson and Johnson. He was also a founding member and head of R&D at MedNova Ltd, a company that pioneered carotid stenting and was acquired by Abbott Vascular. Eamon is passionate about bringing medical therapies to market that impact patients with poor prognostic outlook and he sees team building and technological innovation as critical to better patient outcomes. When he isn’t encouraging his team to challenge themselves to continuously improve, Eamon relaxes by working the land in his home near Galway.
William Abraham, MD The Ohio State University
Professor of Medicine, Physiology, and Cell Biology;
College of Medicine Distinguished Professor
The Ohio State University, Columbus, Ohio
Dr. Abraham is a College of Medicine Distinguished Professor at The Ohio State University. In various leadership positions there, he has developed one of the largest academic programs of Cardiovascular Medicine in the U.S. His heart failure research activities have contributed to the approval and adoption of several new drug and device therapies, including beta-blockers, cardiac resynchronization therapy and implantable hemodynamic monitoring. His research interests include the role of the kidney in heart failure, neurohormonal mechanisms in heart failure, and congestion in acute decompensated heart failure. He has authored more than 1,000 original papers, abstracts, book chapters, and review articles. In 2022, he won the HFSA Pioneer Award. Dr. Abraham is board certified in Internal Medicine and Advanced Heart Failure and Transplant Cardiology.
George Bakris, MD University of Chicago
Professor of Medicine, Nephrology and Director,
Comprehensive Hypertension Center
University of Chicago, Chicago, IL
In Memoriam
Dr. George Bakris was a valued member of the WhiteSwell Scientific Advisory Board. We are grateful for his contributions and will miss his support, guidance and insight.
Dr. Bakris was Professor of Medicine and Director of the American Heart Association Comprehensive Hypertension Center at the University of Chicago Medicine. He was involved in the leadership of a number of national and international trials that investigated declines in the rate of kidney function as well as blood pressure control. He was a member of the National Kidney Foundation’s Board of Directors. He also served as an expert member on the Cardio-Renal Advisory Board of the FDA and an advisor to CMS. Dr. Bakris served as president of the American College of Clinical Pharmacology and the American Society of Hypertension (ASH). He published over 1,000 articles and book chapters in the areas of hypertension, diabetic kidney disease and progression of nephropathy. In 2019 he was awarded the Irvine Page and Alva Bradley Lifetime Achievement Award, Council on Hypertension, American Heart Association. Dr. Bakris was board certified in Internal Medicine and Nephrology.
G. Michael Felker, MD Duke University School of Medicine
Director, Cardiovascular Research, DCRI and
Vice-Chief of Cardiology for Clinical Research Duke University School of Medicine,
Durham, North Carolina
Dr. Felker is Director of Cardiovascular Research at the Duke Clinical Research Institute and Vice-Chief for Clinical Research in the Division of Cardiology. He has served on the executive and steering committees of multiple international clinical trials in heart failure, with a research focus on acute and chronic heart failure, congestion, and the use of biomarkers as diagnostics, prognostic, and therapeutic tools. He is currently President-elect of the Heart Failure Society of America. He has authored more than 430 original papers, book chapters, and review articles and holds editorial board positions on multiple peer-reviewed journals. Dr. Felker is board certified in Internal Medicine and Advanced Heart Failure and Transplant Cardiology.
Michael Jonas, MD Kaplan Medical Center
Director, Structural Heart Disease, Cardiac Catheterization Services
Kaplan Medical Center, Heart Institute Rehovot, Israel
Professor, Hadassah Medical School, Jerusalem
Dr. Jonas is the director of structural heart disease and cardiac catheterization services at Kaplan Medical Center, where he built the program to include complex coronary, peripheral and structural interventions. He is a Professor of Internal Medicine, Cardiology at the Hebrew University, Hadassah Medical School, Jerusalem. Actively involved with cardiovascular medical technology device start-ups, he plays a hands-on development role with bench, preclinical and clinical work. He has published numerous articles in peer-reviewed journals and has presented his work at international cardiovascular conferences. Dr. Jonas is an interventional cardiologist who completed fellowships at Brigham and Women’s Hospital, Harvard Medical School.
Anu Lala-Trindade, MD Mount Sinai Hospital
Program Director,
Advanced Heart Failure and Transplant Fellowship, Director of Heart Failure Research
Mount Sinai Hospital / Zena and Michael A. Wiener Cardiovascular Institute
Dr. Lala is an associate professor of medicine at the Zena & Michael A Wiener Cardiovascular Institute and in the Department of Population Health Science and Statistics at Icahn School of Mount Sinai and Mount Sinai Hospital. She is principle investigator on a number of heart failure clinical trials. She believes in a patient-centered approach, where each individual’s unique needs and preferences are essential components of developing a personalized treatment plan. She serves as the Deputy Editor of the Journal of Cardiac Failure. In 2020, she was recognized with the Proctor H. Harvey Teaching Award by the American College of Cardiology which honors a promising young member of the College who has distinguished herself by dedication and skill in teaching. Dr. Lala is board certified in Internal Medicine, Cardiovascular Medicine and Advanced Heart Failure and Transplant Cardiology.
JoAnn Lindenfeld, MD Vanderbilt University Medical Center
Professor of Medicine, Medical Director
Vanderbilt University Medical Center, Nashville, TN
Dr. Lindenfeld is director of research for VUMC’s Heart Failure and Transplant Section, where she oversees studies of heart failure treatments, including medical treatments, the use of cutting-edge devices and transplantation. She is currently a member of the steering committee for several ongoing international trials. She has served on the FDA Cardiorenal Advisory Panel, the Cardiovascular Devices Panel and continues to be an ad hoc member of both panels. Among her leadership roles, she served as President of the Heart Failure Society of America. She has authored more than 400 original papers, abstracts, book chapters, and review articles. In 2022, she won the HFSA Lifetime Achievement Award. Dr. Lindenfeld is board certified in Internal Medicine and Advanced Heart Failure and Transplant Cardiology.
Parkmore Business Park West
Parkmore, Galway, H91 PTT8
Ireland